{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:27:39Z","timestamp":1790706459611,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K08517"],"award-info":[{"award-number":["22K08517"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12185-025-04102-0","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T07:14:38Z","timestamp":1763363678000},"page":"811-817","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Advances in treatment of chronic graft-versus-host disease"],"prefix":"10.1007","volume":"123","author":[{"given":"Takanobu","family":"Morishita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4881-0427","authenticated-orcid":false,"given":"Yoshihiro","family":"Inamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"issue":"26","key":"4102_CR1","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017;377(26):2565\u201379.","journal-title":"N Engl J Med"},{"issue":"1","key":"4102_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2016-07-686642","volume":"129","author":"SJ Lee","year":"2017","unstructured":"Lee SJ. Classification systems for chronic graft-versus-host disease. Blood. 2017;129(1):30\u20137.","journal-title":"Blood"},{"issue":"8","key":"4102_CR3","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1182\/blood-2014-03-563544","volume":"124","author":"Y Inamoto","year":"2014","unstructured":"Inamoto Y, Flowers ME, Sandmaier BM, Aki SZ, Carpenter PA, Lee SJ, et al. Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. Blood. 2014;124(8):1363\u201371.","journal-title":"Blood"},{"issue":"1","key":"4102_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbmt.2010.05.011","volume":"17","author":"D Wolff","year":"2011","unstructured":"Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M, et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2011;17(1):1\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"4102_CR5","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1182\/blood-2012-11-465583","volume":"121","author":"Y Inamoto","year":"2013","unstructured":"Inamoto Y, Storer BE, Lee SJ, Carpenter PA, Sandmaier BM, Flowers ME, et al. Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. Blood. 2013;121(12):2340\u20136.","journal-title":"Blood"},{"issue":"3","key":"4102_CR6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2033122","volume":"385","author":"R Zeiser","year":"2021","unstructured":"Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, et al. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med. 2021;385(3):228\u201338.","journal-title":"N Engl J Med"},{"issue":"11","key":"4102_CR7","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.bbmt.2008.08.008","volume":"14","author":"SJ Lee","year":"2008","unstructured":"Lee SJ, Astigarraga CC, Eapen M, Artz AS, Davies SM, Champlin R, et al. Variation in supportive care practices in hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008;14(11):1231\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"4102_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1053\/bbmt.2002.v8.pm11846354","volume":"8","author":"SJ Lee","year":"2002","unstructured":"Lee SJ, Vogelsang G, Gilman A, Weisdorf DJ, Pavletic S, Antin JH, et al. A survey of diagnosis, management, and grading of chronic GVHD. Biol Blood Marrow Transplant. 2002;8(1):32\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"4102_CR9","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/j.bbmt.2011.03.006","volume":"17","author":"J Pidala","year":"2011","unstructured":"Pidala J, Lee SJ, Quinn G, Jim H, Kim J, Anasetti C. Variation in management of immune suppression after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17(10):1528\u201336.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"4102_CR10","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3390\/cells14040238","volume":"14","author":"T Morishita","year":"2025","unstructured":"Morishita T, Martin PJ, Inamoto Y. Treatment response in individual organs affected by chronic graft-versus-host disease. Cells. 2025;14(4):238.","journal-title":"Cells"},{"issue":"10","key":"4102_CR11","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/s41409-024-02370-8","volume":"59","author":"G Vadakkel","year":"2024","unstructured":"Vadakkel G, Eng S, Proli A, Ponce DM. Updates in chronic graft-versus-host disease: novel treatments and best practices in the current era. Bone Marrow Transplant. 2024;59(10):1360\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"4102_CR12","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.bbmt.2010.06.015","volume":"16","author":"D Wolff","year":"2010","unstructured":"Wolff D, Gerbitz A, Ayuk F, Kiani A, Hildebrandt GC, Vogelsang GB, et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant. 2010;16(12):1611\u201328.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"4102_CR13","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1200\/JCO.22.00509","volume":"41","author":"DB Miklos","year":"2023","unstructured":"Miklos DB, Abu Zaid M, Cooney JP, Albring JC, Flowers M, Skarbnik AP, et al. Ibrutinib for first-line treatment of chronic graft-versus-host disease: results from the randomized phase III integrate study. J Clin Oncol. 2023;41(10):1876\u201387.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4102_CR14","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1182\/blood-2017-03-775767","volume":"130","author":"PJ Martin","year":"2017","unstructured":"Martin PJ, Storer BE, Inamoto Y, Flowers MED, Carpenter PA, Pidala J, et al. An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. Blood. 2017;130(3):360\u20137.","journal-title":"Blood"},{"issue":"2","key":"4102_CR15","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1182\/blood-2011-01-330217","volume":"118","author":"Y Inamoto","year":"2011","unstructured":"Inamoto Y, Flowers ME, Lee SJ, Carpenter PA, Warren EH, Deeg HJ, et al. Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. Blood. 2011;118(2):456\u201363.","journal-title":"Blood"},{"issue":"10","key":"4102_CR16","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.3324\/haematol.2014.109611","volume":"99","author":"Y Inamoto","year":"2014","unstructured":"Inamoto Y, Martin PJ, Storer BE, Palmer J, Weisdorf DJ, Pidala J, et al. Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease. Haematologica. 2014;99(10):1618\u201323.","journal-title":"Haematologica"},{"issue":"21","key":"4102_CR17","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","volume":"130","author":"D Miklos","year":"2017","unstructured":"Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130(21):2243\u201350.","journal-title":"Blood"},{"issue":"15","key":"4102_CR18","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","volume":"122","author":"JA Dubovsky","year":"2013","unstructured":"Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539\u201349.","journal-title":"Blood"},{"issue":"11","key":"4102_CR19","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1172\/JCI75328","volume":"124","author":"JA Dubovsky","year":"2014","unstructured":"Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B, et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest. 2014;124(11):4867\u201376.","journal-title":"J Clin Invest"},{"issue":"25","key":"4102_CR20","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1182\/blood-2016-06-715284","volume":"128","author":"CE Ryan","year":"2016","unstructured":"Ryan CE, Sahaf B, Logan AC, O\u2019Brien S, Byrd JC, Hillmen P, et al. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood. 2016;128(25):2899\u2013908.","journal-title":"Blood"},{"issue":"10","key":"4102_CR21","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.jtct.2021.05.019","volume":"27","author":"N Doki","year":"2021","unstructured":"Doki N, Toyosaki M, Shiratori S, Osumi T, Okada M, Kawakita T, et al. An open-label, single-arm, multicenter study of ibrutinib in Japanese patients with steroid-dependent\/refractory chronic graft-versus-host disease. Transplant Cell Ther. 2021;27(10):867.","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"4102_CR22","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1038\/leu.2015.212","volume":"29","author":"R Zeiser","year":"2015","unstructured":"Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29(10):2062\u20138.","journal-title":"Leukemia"},{"issue":"6","key":"4102_CR23","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.bbmt.2017.12.797","volume":"24","author":"MA Schroeder","year":"2018","unstructured":"Schroeder MA, Choi J, Staser K, DiPersio JF. The role of janus kinase signaling in graft-versus-host disease and graft versus leukemia. Biol Blood Marrow Transplant. 2018;24(6):1125\u201334.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"4102_CR24","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1200\/JCO-24-02477","volume":"43","author":"R Zeiser","year":"2025","unstructured":"Zeiser R, Russo D, Ram R, Hashmi SK, Chakraverty R, Middeke JM, et al. Ruxolitinib in patients with corticosteroid-refractory or corticosteroid-dependent chronic graft-versus-host disease: 3-year final analysis of the phase III REACH3 study. J Clin Oncol. 2025;43(23):2566\u201371.","journal-title":"J Clin Oncol"},{"issue":"14","key":"4102_CR25","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s40265-021-01593-z","volume":"81","author":"HA Blair","year":"2021","unstructured":"Blair HA. Belumosudil: first approval. Drugs. 2021;81(14):1677\u201382.","journal-title":"Drugs"},{"issue":"17","key":"4102_CR26","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1182\/blood-2015-10-678706","volume":"127","author":"R Flynn","year":"2016","unstructured":"Flynn R, Paz K, Du J, Reichenbach DK, Taylor PA, Panoskaltsis-Mortari A, et al. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016;127(17):2144\u201354.","journal-title":"Blood"},{"issue":"5","key":"4102_CR27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1358\/dot.2022.58.5.3400705","volume":"58","author":"B Taylor","year":"2022","unstructured":"Taylor B, Cohen J, Tejeda J, Wang TP. Belumosudil for chronic graft-versus-host disease. Drugs Today. 2022;58(5):203\u201312.","journal-title":"Drugs Today"},{"issue":"22","key":"4102_CR28","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1182\/blood.2021012021","volume":"138","author":"C Cutler","year":"2021","unstructured":"Cutler C, Lee SJ, Arai S, Rotta M, Zoghi B, Lazaryan A, et al. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. 2021;138(22):2278\u201389.","journal-title":"Blood"},{"issue":"10","key":"4102_CR29","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1002\/ajh.27424","volume":"99","author":"Y Inamoto","year":"2024","unstructured":"Inamoto Y, Kato K, Kawakita T, Onishi Y, Matsuoka KI, Shiratori S, et al. An open-label study of belumosudil, a selective ROCK2 inhibitor, as second or subsequent line of therapy for steroid-dependent\/steroid-resistant chronic GVHD. Am J Hematol. 2024;99(10):1917\u201326.","journal-title":"Am J Hematol"},{"issue":"9","key":"4102_CR30","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1172\/JCI133909","volume":"130","author":"L Jardine","year":"2020","unstructured":"Jardine L, Cytlak U, Gunawan M, Reynolds G, Green K, Wang XN, et al. Donor monocyte-derived macrophages promote human acute graft-versus-host disease. J Clin Invest. 2020;130(9):4574\u201386.","journal-title":"J Clin Invest"},{"issue":"1","key":"4102_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2016-06-686618","volume":"129","author":"KP MacDonald","year":"2017","unstructured":"MacDonald KP, Hill GR, Blazar BR. Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood. 2017;129(1):13\u201321.","journal-title":"Blood"},{"issue":"10","key":"4102_CR32","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1200\/JCO.22.00958","volume":"41","author":"CL Kitko","year":"2023","unstructured":"Kitko CL, Arora M, DeFilipp Z, Zaid MA, Di Stasi A, Radojcic V, et al. Axatilimab for chronic graft-versus-host disease after failure of at least two prior systemic therapies: results of a phase I\/II study. J Clin Oncol. 2023;41(10):1864\u201375.","journal-title":"J Clin Oncol"},{"issue":"18","key":"4102_CR33","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1182\/blood-2017-01-758854","volume":"129","author":"J Du","year":"2017","unstructured":"Du J, Paz K, Flynn R, Vulic A, Robinson TM, Lineburg KE, et al. Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-beta production. Blood. 2017;129(18):2570\u201380.","journal-title":"Blood"},{"issue":"10","key":"4102_CR34","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1172\/JCI75935","volume":"124","author":"KA Alexander","year":"2014","unstructured":"Alexander KA, Flynn R, Lineburg KE, Kuns RD, Teal BE, Olver SD, et al. CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease. J Clin Invest. 2014;124(10):4266\u201380.","journal-title":"J Clin Invest"},{"issue":"11","key":"4102_CR35","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2401537","volume":"391","author":"D Wolff","year":"2024","unstructured":"Wolff D, Cutler C, Lee SJ, Pusic I, Bittencourt H, White J, et al. Axatilimab in recurrent or refractory chronic graft-versus-host disease. N Engl J Med. 2024;391(11):1002\u201314.","journal-title":"N Engl J Med"},{"key":"4102_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2024.107611","volume":"147","author":"V Wais","year":"2024","unstructured":"Wais V, Gantner A, Strauss K, Neagoie A, Weidt C, Schnell J, et al. Treatment of steroid-refractory acute\/chronic graft versus host disease: a single-center real-world experience of ruxolitinib in combination with extracorporeal photopheresis in a high-risk population. Leuk Res. 2024;147:107611.","journal-title":"Leuk Res"},{"issue":"3","key":"4102_CR37","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41409-024-02476-z","volume":"60","author":"MM Chin","year":"2025","unstructured":"Chin MM, Tamaresis JS, Johnston LJ, Lowsky R, Meyer E, Muffly L, et al. Belumosudil combination therapy for chronic graft-versus-host-disease in real-world clinical practice. Bone Marrow Transplant. 2025;60(3):393\u20135.","journal-title":"Bone Marrow Transplant"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04102-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04102-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04102-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:08:25Z","timestamp":1782468505000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04102-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4102"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04102-0","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y.I. is a lead reviewer for the International Journal of Hematology. T.M. declares no conflicts of interest. Y.I. has received honoraria from Novartis, Janssen, and Meiji Seika Pharma, and research grants from Meiji Seika Pharma and Incyte.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}